|Bid||138.70 x 900|
|Ask||139.30 x 800|
|Day's range||137.91 - 140.00|
|52-week range||118.62 - 148.32|
|Beta (3Y Monthly)||0.53|
|PE ratio (TTM)||276.44|
|Earnings date||11 Oct 2016 - 17 Oct 2016|
|Forward dividend & yield||3.60 (2.58%)|
|1y target est||145.63|
Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
SINGAPORE (AP) — Asian markets rose on Wednesday as robust U.S. corporate earnings and encouraging data assuaged worries about softening global growth.
Stocks that moved substantially or traded heavily on Tuesday: Johnson & Johnson, up $2.61 to $136.56 The health care products company reported higher sales of prescription drugs. Goldman Sachs Group Inc., ...
The Nasdaq led stocks higher Tuesday as Adobe spiked and Dow stocks buzzed after Johnson & Johnson, UnitedHealth and Goldman Sachs reported.
The stock market was sharply higher late Tuesday, helped in part by strong earnings from top stocks in the Dow like UnitedHealth Group and Johnson & Johnson.
Ryan McQueeney recaps the morning's top pre-market earnings reports from Goldman Sachs, Morgan Stanley, and Johnson & Johnson. Later, he is joined by Zacks Strategist Dave Bartosiak to discuss upcoming reports from Netflix and IBM.
A jump in prescription drug sales and a sharply reduced tax bill boosted Johnson & Johnson's third-quarter sales and profit, which beat Wall Street expectations. The world's biggest maker of health care products on Tuesday also slightly raised its profit forecast for the year. The New Brunswick, N.J., maker of baby products, biotech drugs and medical devices reported net income of $3.93 billion, or $1.44 per share, up 4.5 percent from a year earlier.